Pseudouridine represents a potential novel risk factor for ovarian cancer. Triglycerides may play a key role in rapidly fatal ovarian tumors, with different associations by acyl carbon content and saturation.
Introduction
Ovarian cancer is the fifth leading cause of female cancer death in the U.S. (1) . However, there are few known risk factors, such that current risk prediction models have a modest predictive capability. Thus, new strategies and research avenues to identify women at high risk are crucial to help prevent this highly fatal disease.
The metabolome consists of all metabolites, small molecules such as amino acids, carbohydrates and lipids, in a biological system (2) , and reflects the integrated effect of genomics and environmental influences. Notably, advances in technology have led to precise measures of small molecule metabolites that are critical for growth and maintenance of cells in biologic fluids (3, 4) . Several studies have identified specific metabolites as biomarkers of cancer risk. For example, branched chain amino acids were strongly associated with risk of pancreatic cancer (5) and lipid metabolites were strongly inversely associated with risk of aggressive prostate cancer (6) . Further, prediagnostic serum concentrations of metabolites related to alcohol, vitamin E, and animal fats were modestly associated with ER + breast cancer risk (7) , while BMI-related metabolites were more strongly related to increased breast cancer risk (8) . These findings support metabolomics profiling as a valuable strategy for identifying new markers of cancer risk.
Therefore, we used metabolomics assays to quantify several classes of circulating metabolites in plasma samples collected three to twenty-three years prior to ovarian cancer diagnosis within a nested case-control study, and, in an agnostic analysis, assessed their potential as biomarkers of ovarian cancer risk.
Methods

Study Population
We conducted nested case-control studies within the Nurses Health Studies (NHS (9) and NHSII (10) ). The NHS was established in 1976 among 121,700 US female nurses aged 30-55 years, and NHSII was established in 1989 among 116,429 female nurses aged 25-42 years. Participants have been followed biennially by questionnaire to update information on exposure status and disease diagnoses. In 1989-1990, 32 ,826 NHS participants provided blood samples and completed a short questionnaire (9) . Briefly, women arranged to have their blood drawn and shipped with an ice pack, via overnight courier, to our laboratory, where it was processed and separated into plasma, red blood cell, and white blood cell components and frozen in gasketed cryovials in the vapor phase of liquid nitrogen freezers. Between 1996 and 1999, 29,611 NHSII participants provided blood samples and completed a short questionnaire (10) . Premenopausal women (n=18,521) who had not taken hormones, been pregnant, or lactated within the past 6 months provided blood samples drawn 7-9 days before the anticipated start of their next menstrual cycle (luteal phase). Other women (n = 11,090) provided a single 30-mL untimed blood sample. Samples were shipped and processed identically to the NHS samples.
Incident cases of epithelial ovarian cancer were identified through the biennial questionnaires or via linkage with the National Death Index. For women reporting a new ovarian cancer diagnosis or cases identified through death certificates, we obtained related medical records and pathology reports; for cases who had died we linked to the relevant cancer registry when medical records were unattainable. A gynecologic pathologist reviewed the records to confirm the diagnosis and abstract date of diagnosis, invasiveness, stage, and histotype (serous, poorly differentiated [PD], endometrioid, clear cell [CC] , mucinous, other/unknown). Date of death was extracted from the death certificate. Participants diagnosed with invasive disease and who died within 3 years of diagnosis were defined as rapidly fatal cases (11) .
Cases were diagnosed with ovarian cancer three years after blood collection until June 1, 2012 (NHS), or June 1, 2013 (NHSII). Two hundred fifty-three cases of invasive and borderline epithelial ovarian cancer (213 in NHS and 40 in NHSII) were confirmed by medical record review. Cases were matched to one control on: cohort (NHS, NHSII); menopausal status and hormone therapy use at blood draw (premenopausal, postmenopausal and hormone therapy use, postmenopausal and no hormone therapy use, missing/ unknown); menopausal status at diagnosis (premenopausal, postmenopausal, or unknown); age (±1 year), date of blood collection (±1 month); time of day of blood draw (±2 hours); and fasting status (>8 hours or ≤8 hours); women in NHSII who gave a luteal sample were matched on the luteal date (date of the next period minus date of blood draw, ±1 day).
The study protocol was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required.
Metabolite profiling
Plasma metabolites were profiled at the Broad Institute of MIT and Harvard (Cambridge, MA) using three complimentary liquid chromatography tandem mass spectrometry (LC-MS/MS) methods designed to measure polar metabolites and lipids as well as free fatty acids as described previously (12) (13) (14) (15) . For each method, pooled plasma reference samples were included every 20 samples and results were standardized using the ratio of the value of the sample to the value of the nearest pooled reference multiplied by the median of all reference values for the metabolite.
Samples from the two cohorts were run together, with matched case-control pairs (as sets) distributed randomly within the batch, and the order of the case and controls within each pair randomly assigned. Therefore, the case and its control were always directly adjacent to each other in the analytic run, thereby limiting variability in platform performance across matched case-control pairs. In addition, 64 quality control (QC) samples, to which the laboratory was blinded, were also profiled. These were randomly distributed among the participants' samples.
Hydrophilic interaction liquid chromatography (HILIC) analyses of water soluble metabolites in the positive ionization mode were conducted using an LC-MS system comprised of a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp.; Marlborough, MA) coupled to a Q Exactive mass spectrometer (Thermo Fisher Scientific; Waltham, MA). Metabolites were extracted from plasma (10 µL) using 90 µL of acetonitrile/methanol/formic acid (74.9:24.9:0.2 v/v/v) containing stable isotope-labeled internal standards (valine-d8, Sigma-Aldrich; St. Louis, MO; and phenylalanine-d8, Cambridge Isotope Laboratories; Andover, MA). The samples were centrifuged (10 min, 9,000 x g, 4°C), and the supernatants were injected directly onto a 150 x 2 mm, 3 µm Atlantis HILIC column (Waters; Milford, MA). The column was eluted isocratically at a flow rate of 250 µL/min with 5% mobile phase A (10 mM ammonium formate and 0.1% formic acid in water) for 0.5 minute followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1% formic acid) over 10 minutes. MS analyses were carried out using electrospray ionization in the positive ion mode using full scan analysis over 70-800 m/z at 70,000 resolution and 3 Hz data acquisition rate. Other MS settings were: sheath gas 40, sweep gas 2, spray voltage 3.5 kV, capillary temperature 350°C, S-lens RF 40, heater temperature 300°C, microscans 1, automatic gain control target 1e6, and maximum ion time 250 ms. Plasma lipids were profiled using a Shimadzu Nexera X2 U-HPLC (Shimadzu Corp.;
Marlborough, MA). Lipids were extracted from plasma (10 µL) using 190 µL of isopropanol containing 1,2-didodecanoyl-sn-glycero-3-phosphocholine (Avanti Polar Lipids; Alabaster, AL).
After centrifugation, supernatants were injected directly onto a 100 x 2.1 mm, 1.7 µm ACQUITY BEH C8 column (Waters; Milford, MA). The column was eluted isocratically with and centrifuged (10 min, 9,000 x g, 4°C). The supernatants (10 µL) were injected onto a 150 x 2.1 mm ACQUITY BEH C18 column (Waters; Milford, MA). The column was eluted isocratically at a flow rate of 450 µL/min with 20% mobile phase A (0.01% formic acid in water) for 3 minutes followed by a linear gradient to 100% mobile phase B (0.01% acetic acid in acetonitril) over 12 minutes. MS analyses were carried out using electrospray ionization in the negative ion mode using full scan analysis over m/z 70-850. Additional MS settings are: ion spray voltage, -3.5 kV; capillary temperature, 320°C; probe heater temperature, 300 °C; sheath gas, 45; auxiliary gas, 10; and S-lens RF level 60.
Raw data from orbitrap mass spectrometers were processed using TraceFinder 3.3 software (Thermo Fisher Scientific; Waltham, MA) and Progenesis QI (Nonlinear Dynamics; Newcastle upon Tyne, UK) and targeted data from the QTRAP 5500 system were processed using MultiQuant (version 2.1, SCIEX; Framingham, MA). For each method, metabolite identities were confirmed using authentic reference standards or reference samples.
In total, 608 known metabolites were measured in this study. Metabolites with a coefficient of variation (CV) among blinded QC samples higher than 25%, or an intraclass correlation coefficient (ICC) <0.4 were excluded from this analysis (N=132, Supplementary Table 1 ).
Furthermore, metabolites not passing our previously conducted processing delay pilot study (15) were excluded from this analysis (N=56, Supplementary Table 1 ). All metabolites (N=420,
Supplementary Table 1) included in the analysis exhibited good reproducibility within person
over one year (15) . 197 metabolites had no missing values among participant samples. Missing values in metabolites (N=211) with less than 10% missingness were imputed with 1/2 of the minimum value measured for that metabolite. We included a missing value indicator for metabolites (N=12) with more than 10% missingness (see statistical analysis section for further details).
After these quality control exclusions total of 420 metabolites including amino acids, amino acids derivatives, amines, lipids, fatty acids, and bile acids were analyzed in this study.
Continuous metabolite values were transformed to probit scores for all analyses to reduce the influence of skewed distributions and heavy tails on the results and to scale the measured metabolite values to the same range.
Statistical analysis
Identification of individual metabolites associated with risk
Conditional logistic regression was used to evaluate metabolite associations, modeled continuously, with risk of overall ovarian cancer. For metabolites with more than 10% missing values, we added a missing indicator term to the regression model. We present the odds ratios (OR) and 95% confidence intervals (95% CI) for an increase from the 10 th to 90 th percentile in metabolite levels or the indicator variable as appropriate.
In a sensitivity analysis, we compared conditional logistic regression to unconditional logistic regression adjusting for the matching factors and found similar results (data not shown). Thus, subsequent analyses by histotype, rapidly fatal status and time between blood collection and diagnosis were conducted using unconditional logistic regression adjusting for the matching factors, allowing the use of all controls.
We conducted stratified analyses restricting separately to serous/PD tumors (cases=176/controls=252), endometrioid/CC tumors (cases=34/controls=252), premenopausal (cases=82/controls=82) and postmenopausal women (cases=137/controls=137) at blood collection, to participants diagnosed 3-11 years (cases=121/controls=252) and 12-23 years after blood collection (cases=131/controls=252 ), to rapidly fatal cases (defined as death occurring within 3 years of diagnosis; cases=86/controls=252), and to less aggressive tumors (defined as death occurring at least 3 years after diagnosis; cases=138/controls=252). All models were adjusted for matching factors and established ovarian cancer risk factors: duration of oral contraceptive use (none or <3 months, 3 months to 3 years, 3 years to 5 years, more than 5 years), tubal ligation (yes/no) and parity (no children, 1 child, 2 children, 3 children, 4+ children). We calculated heterogeneity by time to diagnosis and tumor aggressiveness using case-only analyses and by menopausal status at blood collection by introducing an interaction term between the metabolite and menopausal status.
A permutation test (N=5000) was used to control the family-wise error rate (i.e. account for multiple testing) while accounting for the correlation structure of metabolites. Case-control status was permuted within a matched case-control pair for conditional logistic regression analyses. To account for all controls included in the subtype analyses using unconditional logistic regression, each control was matched to a case within that analysis, while preserving the initial matching criteria as much as possible. The smallest p-value across all tested metabolites in each permutation run was recorded. The permutation p-value for test of the overall null (no metabolite is associated with ovarian cancer) was estimated as k/(5,001), where k is the number of permutations where the smallest p-value (across all metabolites) was smaller than the smallest observed p-value. We estimated the permutation adjusted p-value for each metabolite by using the stepdown min P approach by Westfall and Young (16) implemented in the R package NPC which is based on the previously computed permutation p-values and accounts for the correlation structure among metabolites.
Identification of groups of metabolites associated with risk
Metabolite Set Enrichment Analysis (MSEA) (17) , implemented in the R package FGSEA (18) , was used to identify groups of molecularly or biologically similar metabolites that were enriched among the metabolites associated with risk of overall ovarian cancer and histotypes. This method ranks the metabolites by the estimated beta coefficient of the association with risk and uses this metric to identify enriched metabolite groups at the two extremes of the distribution of beta estimates (positive/inverse associations). Weighted Gene Co-expression Network Analysis (WGCNA) (19) , implemented in the R package WGCNA uses hierarchical clustering to identify groups of correlated metabolites, called metabolite modules, which reflect a scale-free network topology of the measured metabolites (20) . Modules were derived based on control samples only. Each module was summarized by its first principal component (PC) among all analyzed samples. A score was derived for each metabolite module based on the linear combination of measured metabolite values weighted by their corresponding loadings on the first PC summarizing the module. The score was subsequently used in conditional/unconditional logistic regressions to assess associations with risk of ovarian cancer overall and by histotypes. We report nominal p-values and false discovery rates (FDR) (21) for all metabolite groups and metabolite modules. All analyses were performed using the statistical computing language R (22) .
Results
Study population
Of the 252 cases in the analysis, 176 cases were diagnosed with serous/PD tumors while 34 were classified as endometrioid/CC tumors ( Table 1) The top three metabolites inversely associated with risk were C36:2 phosphatidylcholines (PC) Figure 1) together with the results of the permutation test suggest the existence of a metabolomic signal for overall ovarian cancer and non-serous tumors.
Metabolite groups associated with risk of ovarian cancer
In the MSEA analysis, nine metabolite groups were enriched among metabolites associated with risk of ovarian cancer overall at an FDR ≤0.2 (Figure 2 and Supplementary Table 3 ). The top five associated metabolite groups were organic acids and derivatives, PE plasmalogens, TAGs, cholesteryl esters, PC plasmalogens. Nine metabolite groups were associated with risk of serous/PD tumors with FDR ≤0.20 (Figure 2 and Supplementary Table 3) . The top five associated metabolite groups were: nucleosides, nucleotides and analogues, TAGs, carnitines, sphingomyelins, and alkaloids and derivatives. Finally, eleven metabolite groups were associated with risk of endometrioid/CC tumors at FDR ≤0.20 (Figure 2 and Supplementary Table 3 ).
The top five associated metabolite groups were TAGs, DAGs, fatty acyls, lysophosphatidylserines (LPS), and carnitines. Figure 2) and serous/PD tumors (Supplementary Figure 3) but not with endometrioid/CC tumors (Supplementary Figure 4) . Specifically, TAGs with higher number of acyl carbon atoms and double bonds were associated with increased risk, while TAGs with lower number of acyl carbon atoms and double bonds were associated with decreased risk. We did not observe similar patterns for other lipid classes (Supplementary Figures 2-4) . 
Metabolite modules associated with risk of ovarian cancer
Metabolites associated with ovarian cancer risk by time between blood collection and diagnosis
Hydroxyvitamin D3 was associated with increased risk among participants with blood collection 
Metabolites associated with ovarian cancer risk by tumor aggressiveness
Fifty-three lipid-related metabolites (26 TAGs, 7PCs, 6 LPEs, 3 PEs, 3 LPC, 4DAGs, 2 LPSs, and 2 PSs) showed differences by tumor aggressiveness at heterogeneity p≤0.01 (Supplementary Table 7 ). Seven metabolites (6 TAGs and 1 PSs) were associated with increased risk of rapidly fatal disease with ORs ranging between 2.56 and 3.07 at p≤0.008 but not with risk of less aggressive tumors (p>0.62) with heterogeneity p≤0.001. Several lipid-related metabolite classes (DAGs, LPCs, LPEs, PCs, PEs, PSs, and TAGs with high acyl carbon content and saturation)
were upregulated in rapidly fatal tumors while carnitines were up-regulated in less aggressive tumors ( Supplementary Figure 8) . TAGs with lower acyl carbon content and saturation were inversely associated with less aggressive tumors. Pseudouridine did not show heterogeneity by tumor aggressiveness (heterogeneity p=0.13).
Discussion
We conducted the first large-scale agnostic analysis of metabolomics and risk of ovarian cancer.
We identified a potential novel risk factor, plasma pseudouridine, which was associated with an increased risk of ovarian cancer overall and non-serous tumors. Stronger associations for pseudouridine were observed among cases diagnosed within 3-11 years after blood collection.
We identified several metabolite groups and metabolite modules associated with risk of ovarian cancer risk, as well as multiple subtype-specific associations, that open up new opportunities for assessing novel metabolite pathways involved in ovarian cancer risk.
Pseudouridine
Pseudouridine is a post-transcriptionally modified nucleoside, and is an isomer of uridine.
Cellular RNA contains more than 100 modified nucleosides with pseudouridine being the most abundant (23) . Pseudouridine is produced by pseudouridine synthase by isomerizing uridines from transfer RNA (24) , which is involved in in protein translation, and from spliceosomal snRNA which plays a role in pre-mRNA splicing (25) . Pseudouridine was associated with risk of ovarian cancer and non-serous tumors but not serous tumors. The magnitude of the association between pseudouridine and serous cancer was similar to that of overall ovarian cancer risk though not significant, while the risk estimate for endometrioid/CC tumors was higher. This is likely due, in part, to limited sample sizes in the histotype-specific analyses. Our results suggest that pseudouridine may represent a common etiologic mechanism underlying different histotypes of ovarian cancer, which has been observed for other risk factors, such as aspirin and CRP (11, 26, 27) . In retrospective studies, pseudouridine was elevated in urine (28) and plasma (29) from epithelial ovarian cancer patients compared to healthy controls. This, in combination with our finding that pseudouridine had a stronger association when assessed 3-11 years before diagnosis, suggests that this modified nucleotide may be important in progression of preclinical lesions to fully overt invasive disease, which for high-grade serous ovarian cancer appears to be about 7-9 years (30, 31). Increasing evidence suggests that pseudouridylation plays a role in cancer-associated splicing distributions (25, 32) , which are more variable than in normal tissues, and in which tissuespecific alternative splicing reverts to a default cancer pattern that directly contributes to cellular transformation and cancer progression (33, 34) . This has been observed in serous carcinomas, which have highly dysregulated splicing compared to normal tissue (35) . Further, aberrant pseudouridylation may lead to altered translation and reduced translational fidelity of p53 (36, 37) , which is mutated in nearly all high-grade serous tumors (38) . Another potential mechanism is via circular RNA activity, which is altered due to isomerization of uridine to pseudouridine, and has been shown to be dysregulated in ovarian cancer (39) . Additional research should explore the potential role of pseudouridine in precursor lesions to ovarian cancer and the relation between circulating pseudouridine to ovarian and fallopian tube tissue levels.
Triacylglycerides
Notably, several individual TAGs were nominally related to risk and showed significant heterogeneity by tumor aggressiveness (increased circulating TAG levels were associated with increased risk of rapidly fatal tumors but not less aggressive tumors). TAGs as a group were enriched in the MSEA analysis, and 3 of 7 WCGNA modules related to risk were characterized by TAGs. Long chain fatty acids, a main source of energy in the human body, are stored and transported from the small intestine and liver to peripheral cells in the form of TAGs (40) . Lipid synthesis and metabolism, specifically release of free fatty acids from TAGs, are dysregulated in ovarian tumors, increasing cell migration and invasive potential (41) (42) (43) (44) (49) and coronary heart disease (40) . A recent study identified that TAGs at the extremes of carbon atoms and saturation had differential associations with diabetes risk (50) . We also observed differential associations by TAG fatty acids length and saturation, with higher number of carbon atoms and double bonds related to an increased risk and lower number of carbon atoms and double bonds related to decreased risk, particularly for serous/PD tumors. A similar pattern was observed in a retrospective study of serum samples from high-grade serous ovarian cancer cases and controls (51) . Together with our results, these findings suggest that circulating TAG levels may be a risk biomarker for ovarian cancer, particularly for rapidly fatal tumors. Additional prospective studies are needed to validate these associations in different populations and assess the potential differential role of various TAG species in ovarian carcinogenesis.
Other metabolite groups
A number of metabolite groups and clusters were associated with ovarian cancer risk, including organic acids and derivatives, and SMs, the latter of which was hypothesized a priori as a potential risk biomarker and is discussed elsewhere (Zeleznik el al., in revision (52)). A metabolite module driven by carnitines, organic acids and derivatives, carboxylic acids and derivatives, which included pseudouridine (highly negatively weighted) was associated with decreased risk of overall ovarian cancer and non-serous tumors. This module includes asymmetric dimethylarginine (ADMA), which has been related to risk of cardiovascular disease (53) , and inhibits nitric oxide synthesis and may have antiproliferative properties (54) ; nitric oxide signaling may be involved in ovarian carcinogenesis (55) . LPEs were also represented in two WCGNA modules associated with increased risk of overall ovarian cancer, and one WCGNA module associated with increased risk of endometrioid and CC tumors. LPEs have been shown to increase migration in response to chemotherapy as well as have invasive potential in ovarian cancer cell lines (56) . In MSEA analyses, several metabolite classes had a significant inverse enrichment score, including PE plasmalogens, PC plasmalogens and cholesteryl esters, independent of subtype. PE plasmalogens and PC plasmalogens were highly weighted in the WGCNA-derived module M5 which was inversely associated with risk of endometrioid/CC tumors while cholesteryl esters where highly negatively weighted in M7 which was associated with increased risk of overall ovarian cancer and serous/PD tumors. Notably, C36:2 PC plasmalogen was associated with lower risk of endometrioid/CC tumors (OR=0.11, 95%CI
=0.03-0.35; permutation adjusted p=0.056). Little work has examined these markers in ovarian cancer development or etiology.
Our study has several strengths and limitations. Importantly, this is a prospective metabolomics study of ovarian cancer risk with coverage of multiple different metabolite classes. While we had over 250 total ovarian cancer cases and controls, we had more limited sample sizes for specific histotypes, which have been shown to have different associations for known risk factors (57) . To maximize our power, borderline and tumors of unknown morphology were analyzed together with invasive tumors. We did not include information on family history of ovarian cancer.
However, only 2 of the 252 cases were diagnosed before age 45 suggesting that early onset disease, likely due to high risk mutations, does not play a role in this study. We also applied stringent QC criteria to limit identification of spurious associations. Additional strengths include the long follow-up time and detailed covariate information. A limitation is that we only analyzed blood samples collected at one point in time; however, we previously showed that the majority of the measured metabolites have a high within person stability over time (15) . Further, we do not have an independent validation dataset. As this type of data becomes more common, further population studies are needed to validate the results discussed here, while experimental studies are required to understand the biological mechanisms underlying these associations.
In summary, circulating levels of plasma pseudouridine were associated with higher risk of ovarian cancer 3-23 years before diagnosis, with stronger associations among participants with samples collected closer to diagnosis. Additionally, several metabolite groups and metabolite modules were associated with risk of disease, independent of subtype as well as subtype specific.
While independent prospective studies are needed for validation, our results highlight some potentially important novel metabolites that may play a role in the etiology of ovarian cancer.
Further work is warranted to explore the potential use of these metabolites as targets for prevention and/or predictors of risk of ovarian cancer.
